Rhythm Pharmaceuticals shared its Q3 2026 earnings, showing $92 million in sales from the launch of Imcivree.

Nov 3, 2026, 9:35 AM ETResultsRead the original at Benzinga

Good for RYTM

RYTM reported $92 million in quarterly sales, strong U.S. demand, and first commercial treatment in Japan. Sales, market expansion, and lower royalties outweigh $350 million in deal payments; a $750 million loan adds cash but also debt.

RYTM · Rhythm Pharmaceuticals

AI read · Good for RYTM

The AI's read

The U.S. launch is drawing patients and prescribers, and the first Japanese patients are receiving treatment. The phase 3 study adds another chance to expand use. The amended deal cuts royalty costs, but still includes $350 million in payments. The $750 million loan supports research and sales work but adds debt to repay. Sales and market expansion carry more weight in this update.

Get alerts for RYTM

Follow Rhythm Pharmaceuticals (RYTM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RYTM

Free on the App Store and Google Play, or on the web.